Literature DB >> 9545712

[Structure and activities of drug committees in Germany. Results of a survey of 143 hospitals. Pharmaco-economic Study Group and Rational Drug Therapy of the German Society of Clinical Pharmacology and Therapy].

S Harder1, P Thürmann, A Steioff.   

Abstract

BACKGROUND: To obtain information on the structure, present activities and decision making process of hospital drug committees in Germany in 1995 a questionnaire with 36 items was designed and sent to 450 hospitals in Germany with more than 400 beds. 143 returned questionnaires could be evaluated.
RESULTS: According to hospital size the median value of the annual drug budget 1993 ranged between DM 2.4 Mio for hospitals with less than 500 beds and DM 30.0 Mio for university hospitals with more than 1,000 beds (including blood and blood derived products). In 53% of drug committees a pharmacist held the position of the chairman, followed by medical specialists (32%), (clinical) pharmacologists held this position only in 8% of the hospitals, but in almost 50% of the university hospitals. In most cases all clinical specialties are represented in the drug committee, the number of members ranging between 5 and 40 (median 12). The number of drugs included in the internal drug list ranging between 400 in hospitals with < 500 beds and about 700 in university hospitals was strongly correlated with the number of beds and, interestingly, with the number of drug committee members. Treatment guidelines were implemented mainly for antiinfectives (87%), infusion solutions (30%), antiemetic drugs (5-HT3-receptor antagonists, 27%) and blood and blood-derived products such as intravenous immunoglobulins (23%). However, effective control of these guidelines was only performed in about 50% of the hospitals. A drug information service was provided in most hospitals, where 95% of queries were answered by pharmacists.
CONCLUSION: The results of our survey showed, that German hospital drug committees vary considerably with regard to their function and control mechanisms on drug use. Most of the responders would appreciate a more intensive exchange of current problems and treatment guidelines.

Entities:  

Mesh:

Year:  1998        PMID: 9545712     DOI: 10.1007/BF03043288

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  29 in total

1.  Drug use in academic medical centres in an era of ferment.

Authors:  J Avorn
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

2.  Hospital pharmacy committees in England: Their structure, function, and development.

Authors:  A W Brown; C W Barrett; A Herxheimer
Journal:  Br Med J       Date:  1975-02-08

3.  The formulary: an educational tool for clinical pharmacology.

Authors:  R A Branch; P E Johnston; J A Koestner; R Bluhm; C W Stratton; J R Knight
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

4.  Quality control of hospital formularies.

Authors:  T D Rucker
Journal:  Pharm Weekbl Sci       Date:  1988-08-19

5.  Effect of pharmacist interventions on drug therapy costs in a surgical intensive-care unit.

Authors:  C I Miyagawa; J O Rivera
Journal:  Am J Hosp Pharm       Date:  1986-12

6.  [How many beta-receptor blockers does the physician need?].

Authors:  D Palm
Journal:  Klin Wochenschr       Date:  1987-03-16

7.  Management of a restricted drugs policy in hospital: the first five years' experience.

Authors:  J Collier; J Foster
Journal:  Lancet       Date:  1985-02-09       Impact factor: 79.321

8.  [Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies].

Authors:  J G Brecht; A Jenke; M E Köhler; S Harder; P Thürmann; N Rietbrock
Journal:  Med Klin (Munich)       Date:  1995-09-15

Review 9.  Formularies: the role of pharmacy-and-therapeutics (P&T) committees.

Authors:  K H Summers; S L Szeinbach
Journal:  Clin Ther       Date:  1993 Mar-Apr       Impact factor: 3.393

10.  Procedure for evaluating nonformulary drug orders.

Authors:  G T Jay; R A Quercia; G Gousse; M S Chow; R Quintiliani
Journal:  Am J Hosp Pharm       Date:  1993-12
View more
  1 in total

1.  Inappropriate crushing information on ward lists: cytotoxic drugs, capsules, and modified release formulations are gravely neglected.

Authors:  Kristina Lohmann; Julia Ferber; Alexander Francesco Josef Send; Walter Emil Haefeli; Hanna Marita Seidling
Journal:  Eur J Clin Pharmacol       Date:  2014-01-28       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.